Revelation Biosciences, Inc.
Revelation Biosciences, Inc. (REVB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · REVB · as of Dec 31, 2022
Ownership Breakdown
10
Institutional Holders
▼ 3 vs Q3
$426,913
Total Inst. Value
▼ $161,662 vs Q3
3.91M
Shares Outstanding
freeFloat 74.05%
2.24M
13F Shares Held
▼ 7,959 vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
REVB largest shareholders · institutional ownership
Q4 2022 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
AXA S.A. pharmaceutical preparations | 1.96M | 26.15% | 26.15% | $372.41M | Feb 14, 2023 | — held |
STATE STREET CORP pharmaceutical preparations | 108.8K | 1.45% | 1.45% | $20.88M | May 15, 2023 | — held |
REBALANCE, LLC pharmaceutical preparations | 85.8K | 1.15% | 1.15% | $16.32M | Feb 27, 2023 | NEW |
TWO SIGMA SECURITIES, LLC pharmaceutical preparations | 39.4K | 0.53% | 0.53% | $7.49M | Feb 14, 2023 | ▲ 17.6K |
MAYFLOWER FINANCIAL ADVISORS, LLC pharmaceutical preparations | 21.4K | 0.29% | 0.29% | $4.07M | Jan 25, 2023 | — held |
VALEO FINANCIAL ADVISORS, LLC pharmaceutical preparations | 10.0K | 0.13% | 0.13% | $1.90M | Feb 9, 2023 | — held |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 8.5K | 0.11% | 0.11% | $2.00M | Feb 10, 2023 | ▼ 312 |
CWM, LLC pharmaceutical preparations | 4.4K | 0.06% | 0.06% | $1.00M | Feb 1, 2023 | — held |
MORGAN STANLEY pharmaceutical preparations | 4.3K | 0.06% | 0.06% | $815,000 | Feb 14, 2023 | — held |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 119 | 0.00% | 0.00% | $23,000 | Feb 13, 2023 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2022 vs prior quarter
Q4 2022
1
Increased
+17.6K shares2
New Positions
first time holders1
Decreased
−312 shares6
Sold Out
fully exitedNet shares change (top 50)
+17.3K
+17.6K / −312
Net new holders
-4
2 new / 6 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
REVB insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Rolke James Chief Executive Officer | Apr 30, 2026 | Tax Withhold | 10,115 | $1.13 | $11.4K | 214.7K | Form 4 ↗ |
Zygmont Chester Stanley III Chief Financial Officer | Apr 30, 2026 | Tax Withhold | 13,285 | $1.10 | $14.6K | 92.1K | Form 4 ↗ |
ROPER JESS director | Feb 3, 2026 | Tax Withhold | 1,591 | $1.85 | $2.9K | 12.8K | Form 4 ↗ |
Chawla Lakhmir S director | Feb 3, 2026 | Tax Withhold | 2,261 | $1.85 | $4.2K | 12.2K | Form 4 ↗ |
CARVER JENNIFER director | Feb 3, 2026 | Tax Withhold | 1,661 | $1.87 | $3.1K | 12.8K | Form 4 ↗ |
Rolke James Chief Executive Officer | Feb 3, 2026 | Tax Withhold | 8,521 | $1.86 | $15.8K | 224.9K | Form 4 ↗ |
Zygmont Chester Stanley III Chief Financial Officer | Feb 4, 2026 | Tax Withhold | 13,100 | $1.65 | $21.6K | 105.3K | Form 4 ↗ |
Rolke James Chief Executive Officer | Jan 8, 2026 | Award | 532,829 | $0.90 | $479.5K | 933.5K | Form 4 ↗ |
Zygmont Chester Stanley III Chief Financial Officer | Jan 8, 2026 | Award | 78,145 | $0.90 | $70.3K | 473.8K | Form 4 ↗ |
CARVER JENNIFER director | Jan 8, 2026 | Award | 41,981 | $0.90 | $37.8K | 57.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Revelation Biosciences, Inc. (REVB) is primarily owned by institutional investors, who hold approximately 57.4% of total shares outstanding. Company insiders own approximately 25.95%, while retail and public investors account for the remaining 16.70%.
The largest institutional shareholder of Revelation Biosciences, Inc. is AXA S.A., holding approximately 1.96 million shares — equal to 26.15% of outstanding shares — as of December 31, 2022.
A total of 10 institutional investors currently hold REVB stock, with a combined institutional value of approximately $426,913 as of the most recent 13F filing period.
Frequently asked questions
REVB ownershipRevelation Biosciences, Inc. (REVB) is primarily owned by institutional investors, who hold approximately 57.4% of shares. The largest shareholder is AXA S.A. with a 26.15% stake. Company insiders hold 25.95%. Data sourced from SEC Form 13F as of December 31, 2022.